Experimental DNA vaccine targets HPV to fight precancerous cervical cells
NCT ID NCT06276101
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a DNA vaccine called NWRD08 in 9 women with high-grade cervical lesions caused by HPV types 16 or 18. The vaccine was given as a shot followed by a mild electrical pulse to help cells take it up. The main goal was to check safety and see if the vaccine triggers an immune response against the virus.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NWRD08 (DNA plasmid vaccine targeting HPV-16 and HPV-18)
- What this could lead to
- If successful, this could point toward a treatment that clears HPV infection and prevents cervical lesions from becoming cancer.
- What could go wrong
- This is a very early Phase 1 trial with only 9 participants, so safety and immune response are the main focus—not yet proof of effectiveness. The vaccine may not produce strong enough immunity or may cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.